Your Cart

Quarterly Activity Report for 31 December 2020 — Appendix 4C

Quarterly Activity Report for 31 December 2020 — Appendix 4C

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 December 2020 (Q4 FY2020).

Q4 Highlights:

  • Raised $5.6 million (net of costs) in oversubscribed placement, with funds to be used on product development and manufacturing scale-up
  • MagSenseTM HER2 breast cancer Phase I study open for enrolment, with Monash Health established as first clinical site

Read the Quarterly Activity Report for December 31, 2020.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.